Results from a modelling study have showed that cross-protective efficacy of GlaxoSmithKline’s Cervarix® against cervical cancer-causing human papillomavirus (HPV) types1,2 could provide greater public health cost reductions than the cost reductions potentially offered by Gardasil® due to its efficacy against genital warts.
By medicalnewstoday.com
Leave a Reply
You must be logged in to post a comment.
- EXCLUSIVE: Sen. Olympia Snowe Explains Her Lone ‘Yes’ to Health Care Bill
- ‘Mentally-ill’ Briton faces execution in China
- Iraq approves return of small British force
- Boyzone member death cause revealed
- Clinton: Russia yet to back Iran sanctions
- ‘Herminator’ Maier calls time on skiing career
- U.S. official: Turkey’s delay of exercise political
- Arrests of 10 linked to Basque separatists
- Bomber: I regret trying to kill Thatcher
- Unable to scream because her throat had been slit